DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,122 filers reported holding DANAHER CORPORATION in Q2 2024. The put-call ratio across all filers is 1.04 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $252,099 | +1.3% | 1,009 | 0.0% | 0.04% | -20.4% |
Q1 2024 | $248,840 | +6.7% | 1,009 | +0.1% | 0.05% | +40.0% |
Q4 2023 | $233,191 | +93176.4% | 1,008 | 0.0% | 0.04% | -12.5% |
Q3 2023 | $250 | +3.3% | 1,008 | 0.0% | 0.04% | +5.3% |
Q2 2023 | $242 | -4.7% | 1,008 | 0.0% | 0.04% | 0.0% |
Q1 2023 | $254 | -5.2% | 1,008 | 0.0% | 0.04% | -2.6% |
Q4 2022 | $268 | -99.9% | 1,008 | 0.0% | 0.04% | +11.4% |
Q3 2022 | $260,000 | +1.6% | 1,008 | 0.0% | 0.04% | +9.4% |
Q2 2022 | $256,000 | -13.5% | 1,008 | 0.0% | 0.03% | +3.2% |
Q1 2022 | $296,000 | -10.8% | 1,008 | 0.0% | 0.03% | -6.1% |
Q4 2021 | $332,000 | +8.1% | 1,008 | 0.0% | 0.03% | 0.0% |
Q3 2021 | $307,000 | +13.3% | 1,008 | 0.0% | 0.03% | +17.9% |
Q2 2021 | $271,000 | +19.4% | 1,008 | 0.0% | 0.03% | +12.0% |
Q1 2021 | $227,000 | -15.3% | 1,008 | -16.6% | 0.02% | -24.2% |
Q4 2020 | $268,000 | +3.1% | 1,208 | 0.0% | 0.03% | -15.4% |
Q3 2020 | $260,000 | +21.5% | 1,208 | 0.0% | 0.04% | -4.9% |
Q2 2020 | $214,000 | – | 1,208 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |